Pulse Biosciences announced that its first‑in‑human study of the nPulse™ Vybrance™ System achieved an average 74 % reduction in benign thyroid nodule volume, measured 15 to 22 months after treatment. The study reported no tissue regrowth and no serious adverse events, underscoring the durability and safety of the nanosecond pulsed field ablation (nsPFA) technology.
"These long‑term data from the initial feasibility study provide an early view into the potential of nPulse Vybrance for the durable ablation of benign thyroid nodules. Within this feasibility study we were able to demonstrate significant volume reduction, without regrowth or serious adverse events out to 15 to 22 months," said CEO Paul LaViolette.
"Of the patients treated in this study, 100 percent were highly satisfied with their cosmetic appearance, and 95 percent were highly satisfied with their overall treatment, which is encouraging given the duration of follow‑up in this feasibility study. This study provides the foundation for future research in using nsPFA energy, a highly differentiated nonthermal energy source, for the treatment of benign thyroid nodules," added Professor Stefano Spiezia.
The durable results reinforce Pulse’s nsPFA platform, which differentiates the company from thermal ablation competitors by sparing surrounding tissue while effectively destroying target cells. The data support the company’s broader strategy to expand nsPFA into other non‑cardiac indications, with plans for additional clinical studies slated for the second half of 2026. The findings also strengthen the company’s position in the growing benign thyroid nodule market, which is projected to grow at a CAGR of nearly 10 % through 2030.
Pulse’s Q4 2025 financials show a GAAP net loss of $17.4 million and a cash burn of $14.8 million, with $80.7 million in cash and cash equivalents as of December 31 2025. The company has begun a controlled commercial launch of its soft‑tissue ablation product, but the financial results highlight ongoing liquidity constraints and the need for continued investment in clinical development.
The study’s positive clinical outcomes add a compelling milestone to Pulse’s product portfolio, but the company’s financial trajectory remains a key consideration for stakeholders as it pursues further clinical validation and regulatory milestones.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.